Fertility Market - Databook 2025 to 2034

The global fertility market size was evaluated at USD 36,550 million in 2024 and is expected to grow around USD 87,320 million by 2034, registering a CAGR of 9.1% from 2025 to 2034.

Highlights of the Fertility Market

• Europe dominated the global market in 2024.
• North America is anticipated to grow at the fastest rate in the market during the forecast period.
• By offering, the assisted reproductive technology (ART) segment held a dominant presence in the market in 2024.
• By offering, the fertility drugs segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By end user, the fertility clinics segment accounted for a considerable share of the market in 2024.
• By end user, the hospitals segment is predicted to witness significant growth in the market over the forecast period.

Industry Valuation and Growth Rate Projection

The fertility market circumscribes the concept of fertility, which means the ability to conceive a child naturally. This market comprises assisted reproductive technology (ART) treatments alongside fertility medications and mental health services for fertility treatment support. Advances in technology are helping people fulfil their dream of becoming parents.

The market is committed to helping out couples who face any problems concerning infertility, primarily because of the assumption that women are mostly responsible for sterility. The statistics, though, imply that one-third of women and one-third of men are accountable. The other couples, including both partners or the unknown cases, face this issue. Genetic anomalies and prolonged childbirth, along with STIs or sexually transmitted infections, are some of the common reasons why infertility occurs.

Around 10-15% of couples are affected due to the inability to have a child in the United States. The report issued by the Centers for Disease Control and Prevention discovered that tubal infertility affects 18 % of U.S. couples who have given assisted reproduction a try.

Market: Stats and Figures

• According to the National Family Health Survey data (2019-21), the fertility rate is 1.6 in India's urban areas and 2.1 in rural parts. By 2050, India's total fertility rate (TFR) is projected to downturn irrevocably to 1.29.
• In 2022, only 3.88 million babies were born in the EU, demonstrating for the first time that the number went below 4 million.
• As per the study by the National Institutes of Health, males are solely responsible for approximately 20 per cent of infertility cases and play a contributing role in another 30 per cent to 40 per cent of cases.
• In keeping with the Economist Impact report sponsored by Merck, South Korea has the lowest total fertility rate (TFR) in the world at 0.8, while Japan has a rate of 1.3, pointing to the inflation of the fertility market.

How AI Has Benefitted the Market

Artificial intelligence (AI) can alter the personalization of ovarian stimulation protocols by influencing gigantic datasets and advanced analytical procedures. Advances in AI, mostly in machine learning (ML) and deep learning (DL), are proving to improve the precision and effectiveness of these protocols. Originating customized treatments for patients with infertility is possible due to the advent of Artificial Intelligence, by replacing conventional methods, pushing the fertility market further.

• Predictive models: AI algorithms can help with the development of predictive models to foresee embryo viability.
• High-resolution analysis: using DL algorithms, AI can study the sperm movement accurately and multiply the chances of best sperm selection.
• Identification of profiles: The patient profiles and their responses to distinctive stimulation procedures can be distinguished through AI.
• Prophesying treatments: AI can combine data from prior IVF cycles to sharpen up estimates for upcoming treatments.

Industry Leader Announcements

• Dr. Ajay Murdia, Founder and Chairman of Indira IVF:

Reassuring the buildup of a positive mindset about fertility, Dr. Murdia said, "By fostering collaboration among individuals, healthcare professionals, and organizations, society can significantly reduce the stigma surrounding infertility and provide essential support to affected families. This unified approach is vital in creating a supportive environment for those facing fertility challenges and ultimately achieving freedom from the burden of infertility."

Recent Developments:

• Gameto, a US-based company devoted to taking care of women’s reproductive health, has publicized its partnership with IVFAustralia (IVFA), a part of the Virtus Health group, and launched its product, Fertilo.
• GenPrime, with fertility clinics across Asia and North America, has partnered with Genea Fertility from Australia to boost top-notch fertility treatment for patients in Thailand and Southeast Asia.

Geographical Insights 

The global fertility market is experiencing significant growth, with North America maintaining its position as the foremost region while Europe emerges as the fastest-growing market. In the APAC region, countries such as India and Japan are driving growth in the space.

North America

In 2024, North America held an abundant share of the fertility market. This dominance is attributed to the government taking initiatives for cost-friendly treatment of patients in the region.  

• The president of the US has authorized an administrative order that guides the Domestic Policy Council to recommend policies for lessening the IVF-related costs, which may cost up to $25,000 per cycle, in 90 days, and facilitating reasonably priced treatment for people.

Europe

Europe is experiencing significant growth in the market. The major contributory factor behind the same being an extreme downfall in fertility rates within the region, especially in Malta, which was 1.06 live births per woman.

• According to an article in Eurostat, the fertility rate in the European Union went crashing down from 1.46 in 2022 to 1.38 in 2023.

APAC

The Asia Pacific (APAC) region is anticipated to see speedy progress in the fertility market. The countries like South Korea, India, and Japan are among the fastest-growing ones within APAC.

• The fertility rate of Japan has been at its lowest level of 1.26 in 2022, which indicates the seventh consecutive year of deterioration in the country, while the World Bank had informed that the global average could have been 2.4.
• Birla Fertility & IVF, which is India’s third-largest in-vitro fertilization (IVF) network, is going to extend in ASEAN as well as West Asian markets with an investment of ₹500 crore to two-fold the number of centers from the present 50 to 100 in the next few years.

Competitive Landscape 

The market is highly competitive, with the best companies like FUJIFILM IRVINE SCIENTIFIC, Progyny Inc., Vitrolife AB, INVO Bioscience Inc., OvaScience Inc., Cook Medical, and Merck KGaA (MRKC.F) holding the largest chunk of market share. Developing biotech firms also play a crucial role in fostering a lively and budding competitive landscape.

The market is dominated by quite a few pharmaceutical companies renowned for their noteworthy contributions to research and treatment relating to fertility. Based on recent data, the top three leading companies are:

• Company Name: FUJIFILM Holdings Corporation
• Year of Incorporation: 1934
• Headquarters: Tokyo, Japan

The annual revenue of FUJIFILM Holdings Corporation was $2,960,916,000 in 2024.

• Company Name: Progyny, Inc.
• Year of Incorporation: 2008
• Headquarters: New York

The yearly revenue of Progyny, Inc. took a leap from $1,088,598 in 2023 to $1,167,221 in 2024.

• Company Name: Vitrolife AB
• Year of Incorporation: 1994 
• Headquarters: Gothenburg, Sweden

The gross profit of Vitrolife AB rose from $1,977,000 in 2023 to $2,139,000 in 2024.